Biotechnology

Video Chat

STAT Plus video chat: Biotech in uncharted territory

By Adam Feuerstein and Matthew Herper

In the Lab

What it’s like to go into the lab at a biopharma company during the coronavirus pandemic

By Rebecca Robbins and Kate Sheridan

Health

Vir Biotechnology reports early progress in antibody treatment for Covid-19

By Matthew Herper

Adam's Take

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

By Adam Feuerstein

Biotech

Bellus Health hopes to be one of biotech’s more improbable turnarounds

By Damian Garde

Biotech

Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors

By Kate Sheridan

Health

As Covid-19 spreads, disruptions to clinical trial and drug development accelerate

By Adam Feuerstein

Health

Gilead pauses access to experimental Covid-19 drug due to ‘overwhelming demand’

By Matthew Herper

Biotech

Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?

By Maggie Fox

Adam's Take

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

By Adam Feuerstein

Biotech

Anticipating ‘shelter-in-place’ orders across the country, trade groups push for exceptions for biopharma employees

By Rebecca Robbins and Kate Sheridan

Biotech

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

By Adam Feuerstein and Matthew Herper

Biotech

Near-lockdown in the Bay Area ‘ratchets up’ challenges for local biotechs and labs

By Rebecca Robbins

Adam's Take

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

By Adam Feuerstein

Biotech

Merck drug reduces cough frequency but taste alterations could cloud prospects

By Adam Feuerstein

Biotech

Regeneron says potential Covid-19 drugs could start human tests by early summer

By Matthew Herper

Biotech

As the market craters, Keros Therapeutics files for an IPO

By Kate Sheridan

Biotech

Drug makers grounding salespeople as coronavirus impact on business spreads

By Adam Feuerstein

Biotech

How one company made $208 million on an untested coronavirus vaccine

By Damian Garde and Adam Feuerstein

Biotech

Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers

By Anissa Gardizy — Boston Globe

Biotech

Engage touts long-awaited positive data for its inhaler for seizures

By Kate Sheridan

Health

Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals

By Eric Boodman

transmission electron micrograph covid19

Adam's Take

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

By Adam Feuerstein

Biotech

FDA rejects Intarcia’s diabetes implant for a second time

By Kate Sheridan

Biotech

Pace of medical conference shutdowns is accelerating as the coronavirus outbreak spreads

By Adam Feuerstein

biotechnology

Amarin loses legal fight over heart drug patent; shares sink

Biotech VC Bob Nelsen called it right on the coronavirus. Now he has thoughts on therapeutics — and masks

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Could real-world evidence help shape the future of drug development?

STAT Plus video chat: Biotech in uncharted territory

What it’s like to go into the lab at a biopharma company during the coronavirus pandemic

Vir Biotechnology reports early progress in antibody treatment for Covid-19

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Bellus Health hopes to be one of biotech’s more improbable turnarounds

Startup Spotlight: Carisma Therapeutics wants to make a cell therapy that will work in solid tumors

As Covid-19 spreads, disruptions to clinical trial and drug development accelerate

Gilead pauses access to experimental Covid-19 drug due to ‘overwhelming demand’

Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Anticipating ‘shelter-in-place’ orders across the country, trade groups push for exceptions for biopharma employees

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

Near-lockdown in the Bay Area ‘ratchets up’ challenges for local biotechs and labs

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

Merck drug reduces cough frequency but taste alterations could cloud prospects

Regeneron says potential Covid-19 drugs could start human tests by early summer

As the market craters, Keros Therapeutics files for an IPO

Drug makers grounding salespeople as coronavirus impact on business spreads

How one company made $208 million on an untested coronavirus vaccine

Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers

Engage touts long-awaited positive data for its inhaler for seizures

Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

FDA rejects Intarcia’s diabetes implant for a second time

Pace of medical conference shutdowns is accelerating as the coronavirus outbreak spreads